Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
In vivo total antioxidant capacity: comparison of two different analytical methods
Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 42, Issue 1, Pages 84–89, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.016, June 2005
- Published Online:
Several methods to assess the total antioxidant capacity (TAC) are available. However, the final value of measured TAC in the sample depends on the procedure used in every specific assay. This makes crucial the comparison of different analytical methods. The aim of our study was to evaluate analytical characteristics and laboratory reliability of two different assays: the ferric-reducing ability (FRAP) assay and a new spectrophotometric test (OXY-adsorbent test, Diacron, Italy).
Unselected outpatients referred to the Institute of Clinical Physiology were studied (n=187, 58 females, 129 males, mean age: 65±13 years). All blood samples were maintained on ice, centrifuged within 15 minutes after blood collection and then stored at −80°C until performance of assay procedures.
OXY assay: The lower limit of sensitivity was 6 μmol HClO/ml. The assay was found to be linear up to 440 μmol HClO/ml (r=−0.99, p<0.001). Absorbance was linear over a wide concentration range with solutions containing uric acid in purified form (0–1000 μmol/l, r=−0.996, p<0.001), serum (r=−0.99, p<0.01) or plasma serially diluted (r=−0.99, p<0.01). Mean value in plasma samples accounted for 366.2±7.2 μmol HClO/ml. Mean OXY value in females (353.4±13.2 mmol HClO/ml) was not different from that detected in males (372±8.6 mmol HClO/ml). A significant difference was observed between subjects without and with hypertension in serum OXY levels (344.8±9.9 and 383.2±10 μmol HClO/ml, p<0.01, respectively).
FRAP assay: The lower limit of sensitivity was 15 μmol/l. Linearity was observed up to 1000 μmol/l (r=−0.998, p<0.001). Absorbance was linear over a wide concentration range with solutions containing uric acid in purified form (0–1000 μmol/l, r=0.997, p<0.001), serum (r=0.99, p<0.01) or plasma serially diluted (r=0.99, p<0.01). FRAP mean value in plasma samples, evaluated in 102 patients, accounted for 514.1±19.1 μmol/l. Mean FRAP in females (469±22.5 μmol/l) was not different from that detected in males (535±25.6 mmol/l).
FRAP vs. OXY: A significant direct relationship was observed when comparing FRAP with OXY levels in the whole population (r=0.22, p<0.05).
Neither of the methods are expensive and they are speedy and simple to perform. Values are reproducible and linearly correlated to the concentration of antioxidants present in the samples. For this reason, these methods may be considered practicable indicators of total antioxidant capacity, for routinely potential use in every laboratory and useful in all the studies concerning the evaluation of oxidative stress.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.